Compare OABI & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OABI | JRVR |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | 114 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.4M | 265.7M |
| IPO Year | N/A | 2014 |
| Metric | OABI | JRVR |
|---|---|---|
| Price | $1.86 | $6.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $6.67 | ★ $6.75 |
| AVG Volume (30 Days) | ★ 279.2K | 237.8K |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | N/A | ★ 125.82 |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | ★ $687,614,000.00 |
| Revenue This Year | $74.84 | $1.50 |
| Revenue Next Year | $40.54 | N/A |
| P/E Ratio | ★ N/A | $8.11 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $3.85 |
| 52 Week High | $3.33 | $7.20 |
| Indicator | OABI | JRVR |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 41.89 |
| Support Level | $1.68 | $6.28 |
| Resistance Level | $1.89 | $7.02 |
| Average True Range (ATR) | 0.11 | 0.29 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 46.15 | 19.24 |
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.